Piramal Pharma Q3 Profit Falls To ₹129 Crore On Lower Income, Revenue Recovers Sequentially To ₹1,196 Crore

Mumbai: Piramal Pharma Limited reported an 8.5 percent year-on-year rise in standalone net profit to Rs 128.91 crore for the quarter ended December 31, 2025 (Q3 FY26), even as sequential profit dipped 34.3 percent from Rs 196.33 crore in Q2. Revenue from operations stood at Rs 1,195.81 crore, marking a 6.1 percent QoQ rebound but a 4.2 percent decline YoY. Compared to Rs 1,127.26 crore in Q2 and Rs 1,121.36 crore in Q1, the revenue trajectory suggests improving operational momentum despite exceptional charges.

Piramal Pharma Q3 FY26 Results: Mixed Performance with Strong PCH Growth 📊 | MCap 20,470.42 Cr

• Q3 FY26 consolidated revenue: ₹2,140 Cr, down 3% YoY
• 9M FY26 revenue: ₹6,117 Cr, down 4% YoY
• Q3 EBITDA: ₹239 Cr (11% margin), down 32% YoY
• 9M EBITDA: ₹628 Cr (10%… pic.twitter.com/1dYlObXUtr
— Investor Feed (@_Investor_Feed_) January 28, 2026

Standalone performance summary

In Q3 FY26, Piramal Pharma's standalone revenue declined 4.2 percent YoY to Rs 1,195.81 crore from Rs 1,248.32 crore in Q3 FY25, while total income rose marginally by 1.5 percent to Rs 1,291.96 crore. Sequentially, revenue improved from Rs 1,127.26 crore in Q2 FY26. Net profit grew 8.5 percent YoY but declined on a QoQ basis due to a one-time Rs 26.94 crore exceptional loss related to India’s new Labour Codes.

Sequential growth moderates

While revenue grew QoQ, total income actually dipped 2.8 percent due to lower other income (Rs 96.15 crore vs Rs 201.97 crore in Q2). Expenses also rose to Rs 1,110.09 crore, led by higher stock-in-trade purchases and depreciation. Finance costs eased to Rs 16.84 crore from Rs 20.38 crore in Q2. The exceptional item—linked to Labour Code impact—dragged profit before tax to Rs 154.93 crore from Rs 247.41 crore in Q2.

Nine-month performance and outlook

For 9M FY26, revenue stood at Rs 3,292.95 crore, down 8.4 percent from Rs 3,595.91 crore in 9M FY25, while PAT improved 5.9 percent to Rs 438.38 crore. The improvement in profit despite lower revenue reflects cost discipline and operational leverage. With a robust 9M EPS of Rs 3.31, the company shows resilience amid sectoral challenges, indicating steady momentum going into Q4.

Disclaimer: This article is based solely on the company’s unaudited standalone financial results and regulatory filings. It does not constitute investment advice. Readers should consult certified professionals before making financial decisions.